Stopping GLP-1 medications such as semaglutide (Ozempic, Wegovy) can rapidly erase the cardiovascular gains achieved while using them.
A large observational study published in BMJ Medicine tracked outcomes in 333,687 U.S. veterans over three years to assess what happens when people discontinue GLP-1 therapy. Researchers compared 132,551 patients prescribed a GLP-1 to 201,136 patients prescribed a sulfonylurea, another diabetes drug, and reassessed medication status every six months.
Key findings
– Continuous GLP-1 use over three years was associated with an 18% lower risk of major cardiovascular events compared with sulfonylurea use.
– People who stopped GLP-1s after 2 or 2.5 years still showed modest risk reductions (about 7% and 15%, respectively), but those who took the drugs for 18 months or less before stopping did not see a significant benefit.
– Interrupting GLP-1 treatment for just six months before restarting significantly reduced the cardiovascular benefit and was linked to a 4%–8% higher risk versus continuous use.
– Discontinuing GLP-1s for one to two years without resuming was associated with a 14%–22% increased risk of a cardiovascular event compared with continuous therapy.
Why this matters
GLP-1 receptor agonists not only improve blood sugar and promote weight loss but also appear to protect the heart and blood vessels through multiple mechanisms: better glycemic control, modest blood pressure reduction, improved lipid and vascular function, reduced inflammation and atherosclerotic plaque progression, and possible direct protective effects on cardiac tissue. The study suggests those protective effects are cumulative but can be lost quickly when treatment is interrupted.
Practical considerations
Many people stop GLP-1 medications early because of cost, side effects, or supply problems. The study’s authors and other clinicians emphasize that for cardiovascular risk reduction these drugs behave like a long-term preventive therapy rather than a short-term fix: benefits build over time and can disappear relatively fast if therapy is halted.
If you are thinking about stopping a GLP-1:
– Discuss it with your healthcare provider first so risks and alternatives can be reviewed.
– Be aware that stopping may lead to weight regain and loss of the heart-protective effects you gained while on the drug.
– Abrupt discontinuation can produce symptoms such as nausea, increased appetite, weight gain, and changes in blood pressure; some clinicians recommend tapering where medically appropriate so the body adjusts more gradually.
– Maintain healthy eating patterns and regular physical activity to help preserve weight loss and cardiovascular health after stopping medication.
Clinical takeaway
For people taking GLP-1 drugs primarily to reduce cardiovascular risk or manage chronic obesity and diabetes, long-term adherence appears important. Benefits accumulated over months to years can be diminished quickly if therapy is interrupted, so ongoing follow-up and planning for sustained treatment or transition strategies are essential.
If you are on a GLP-1 medication and considering stopping, talk with your clinician to create a plan that minimizes risk and supports long-term heart and metabolic health.